文献速递艾滋病与性传播感染新发突发、热带与寄生虫病

替诺福韦对HIV感染者SARS-CoV-2感染及重症结局的影响:一项倾向评分匹配研究

Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

在西班牙加泰罗尼亚PISCIS前瞻性队列(n=14978)的HIV感染者中,采用倾向评分匹配和校正Cox回归分析,发现替诺福韦(TAF/FTC或TDF/FTC)与SARS-CoV-2诊断率或相关住院风险降低无关,TDF/FTC使用者基线特征本身与更良性感染结局相关。

要点

  • 倾向评分匹配后,TDF/FTC组SARS-CoV-2诊断率低于ABC/3TC组(9.6% vs 12.8%,P=0.021)。
  • 校正模型中,TDF/FTC与ABC/3TC相比,SARS-CoV-2诊断(aOR 0.79;95%CI 0.60-1.04)和住院(aOR 0.51;95%CI 0.15-1.70)均无显著关联。
  • 替诺福韦暴露不应改变任何SARS-CoV-2感染的预防或治疗管理。

核心结论

  • TAF/FTC或TDF/FTC与HIV感染者SARS-CoV-2诊断率或相关住院率降低无关。
  • TDF/FTC使用者基线特征本身与更良性的SARS-CoV-2感染结局相关。
  • 替诺福韦暴露不应改变任何SARS-CoV-2感染的预防或治疗管理。

研究设计与样本

  • 在西班牙加泰罗尼亚的前瞻性PISCIS队列(n=14978)HIV感染者中开展倾向评分匹配分析。
  • 使用校正Cox回归模型评估替诺福韦与SARS-CoV-2结局之间的关联。

主要发现

  • 倾向评分匹配后,TAF/FTC组与ABC/3TC组SARS-CoV-2诊断率相似(11.6% vs 12.5%,P=0.256)。
  • 倾向评分匹配后,TDF/FTC组SARS-CoV-2诊断率低于ABC/3TC组(9.6% vs 12.8%,P=0.021)。
  • 倾向评分匹配后,TDF/FTC组SARS-CoV-2诊断率低于TAF/FTC组(9.6% vs 12.1%,P=0.012)。
  • 充分校正的逻辑回归模型中,TAF/FTC与SARS-CoV-2诊断(aOR 0.90;95%CI 0.78-1.04)或住院(aOR 0.93;95%CI 0.60-1.43)降低无关。
  • 与ABC/3TC相比,TDF/FTC与SARS-CoV-2诊断(aOR 0.79;95%CI 0.60-1.04)或住院(aOR 0.51;95%CI 0.15-1.70)降低无关;与TAF/FTC相比,TDF/FTC与SARS-CoV-2诊断(aOR 0.79;95%CI 0.60-1.04)或相关住院(aOR 0.33;95%CI 0.10-1.07)降低无关。

临床怎么用

  • 替诺福韦暴露不应改变任何SARS-CoV-2感染的预防或治疗管理。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reports on the impact of some antiretrovirals against SARS-CoV-2 infection and disease severity are conflicting. OBJECTIVES: We evaluated the effect of tenofovir as either tenofovir alafenamide/emtricitabine (TAF/FTC) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) against SARS-CoV-2 infection and associated clinical outcomes among people living with HIV (PLWH). METHODS: We conducted a propensity score-matched analysis in the prospective PISCIS cohort of PLWH (n = 14 978) in Catalonia, Spain. We used adjusted Cox regression models to assess the association between tenofovir and SARS-CoV-2 outcomes. RESULTS: After propensity score-matching, SARS-CoV-2 diagnosis rates were similar in TAF/FTC versus ABC/3TC recipients (11.6% versus 12.5%, P = 0.256); lower among TDF/FTC versus ABC/3TC recipients (9.6% versus 12.8%, P = 0.021); and lower among TDF/FTC versus TAF/FTC recipients (9.6% versus 12.1%, P = 0.012). In well-adjusted logistic regression models, TAF/FTC was no longer associated with reduced SARS-CoV-2 diagnosis [adjusted odds ratio (aOR) 0.90; 95% confidence interval (CI), 0.78-1.04] or hospitalization (aOR 0.93; 95% CI, 0.60-1.43). When compared with ABC/3TC, TDF/FTC was not associated with reduced SARS-CoV-2 diagnosis (aOR 0.79; 95% CI, 0.60-1.04) or hospitalization (aOR 0.51; 95% CI, 0.15-1.70). TDF/FTC was not associated with reduced SARS-CoV-2 diagnosis (aOR 0.79; 95% CI, 0.60-1.04) or associated hospitalization (aOR 0.33; 95% CI, 0.10-1.07) compared with TAF/FTC. CONCLUSIONS: TAF/FTC or TDF/FTC were not associated with reduced SARS-CoV-2 diagnosis rates or associated hospitalizations among PLWH. TDF/FTC users had baseline characteristics intrinsically associated with more benign SARS-CoV-2 infection outcomes. Tenofovir exposure should not modify any preventive or therapeutic SARS-CoV-2 infection management.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Nomah DK, Reyes-Urueña J, Díaz Y, et al. Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study. J Antimicrob Chemother. 2022. PMID: 35678461. doi:10.1093/jac/dkac177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。